Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Appelbaum

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Leukemia & Lymphoma|March 10, 2023
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasmsNoam E Kopmar, Ted Gooley, Niall Curley, et al.
The Journal of Clinical Investigation|March 19, 2024
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosingJacob Appelbaum, April E Price, Kaori Oda, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Leukemia & Lymphoma|March 10, 2023
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasmsNoam E Kopmar, Ted Gooley, Niall Curley, et al.
The Journal of Clinical Investigation|March 19, 2024
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosingJacob Appelbaum, April E Price, Kaori Oda, et al.
Pageof 2